{"id":7606,"date":"2018-01-15T12:56:46","date_gmt":"2018-01-15T12:56:46","guid":{"rendered":"https:\/\/jurmed.ro\/medici\/?p=7606"},"modified":"2018-01-15T12:56:46","modified_gmt":"2018-01-15T12:56:46","slug":"ocrevus","status":"publish","type":"post","link":"https:\/\/jurmed.ro\/medici\/ocrevus\/","title":{"rendered":"Ocrevus &#8211; un medicament pentru tratamentul formelor recurente de scleroza multipla si pentru forma primara progresiva"},"content":{"rendered":"<p style=\"text-align: justify\"><strong>Ocrevus &#8211; un nou medicament produs de Roche, pentru tratamentul formelor recurente de scleroza multipla si pentru forma primara progresiva, a fost aprobat in Uniunea Europeana <\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li><strong>Primul \u015fi unicul medicament cu beneficii majore aprobat in prezent in Uniunea Europeana, pentru pacien\u0163ii care sufera de scleroza multipla primar progresiva (PPMS) in stadiu incipient<\/strong><\/li>\n<li><strong>O noua op\u0163iune importanta de tratament pentru pacien\u0163ii care sufera de forme recurente de scleroza multipla (RMS)<\/strong><\/li>\n<li><strong>Un profil beneficiu-risc demonstrat in 3 studii de faza III, care au inclus o populatie diversa de pacienti, incluzand si pacienti cu forme incipiente de boala<\/strong><\/li>\n<li><strong>Ocrevus are administrarea intravenoasa la fiecare 6 luni, fara nevoia pentru diferite testari intre administrari<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify\">Roche a anun\u0163at ca prin decizia Comisiei Europene, s- a acordat autoriza\u0163ia de punere in piata pentru un nou medicament destinat tratamentului pacien\u0163ilor adulti cu\u00a0 forme recurente de scleroza multipla, cu boala activa definita prin caracteristici clinice sau imagistice, \u015fi pentru tratamentul pacien\u0163ilor adul\u0163i cu scleroza multipla primar progresiva (SMPP), incipienta, in ceea ce prive\u015fte durata bolii \u015fi nivelul de dizabilitate \u015fi cu caracteristici imagistice ale activita\u0163ii inflamatorii.<\/p>\n<p style=\"text-align: justify\">Scleroza multipla (MS) afecteaza circa 700.000 de persoane in Europa, dintre care aproximativ 96.000 sufera de forma primar progesiva de scleroza multipla, una dintre formele care provoaca invaliditati majore<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a><sup>,<\/sup><a href=\"#_ftn2\" name=\"_ftnref2\">[2]<\/a>. Majoritatea persoanelor diagnosticate cu MS sufera de forma recurenta (RMS) sau primar progresiva (PPMS) la momentul diagnosticarii.<a href=\"#_ftn3\" name=\"_ftnref3\">[3]<\/a><\/p>\n<p style=\"text-align: justify\">\u201d Aprobarea primita din partea Comisiei Europene pentru acest medicament este o veste foarte buna. Acest medicament are potentialul de a fi un punct de cotitura in abordarea \u015fi tratamentul sclerozei multiple,\u201d a afirmat Gavin Giovannoni, Profesor de Neurologie la Barts si London School of Medicine and Dentistry, Queen Mary University din Londra. \u201d<\/p>\n<p style=\"text-align: justify\">Pana la acest medicament, persoanele care sufereau de scleroza multipla primar-progresiva (PPMS), care adesea erau nevoiti sa se deplaseze cu ajutorul unui baston sau scaun cu rotile, sa renunte la locul de munca si sa necesite ingrijire speciala, nu dispuneau de tratamente aprobate care sa incetineasca progresia bolii. Persoanele cu forma recurent-remisiva de scleroza multipla (RMS) adeseori erau nevoiti sa aleaga intre siguranta si eficacitate crescuta a tratamentului. Acest medicament se administreaza o data la \u015fase luni, fara a fi nevoie de monitorizare constanta, ceea ce, speram noi, va ajuta oamenii sa i\u015fi traiasca via\u0163a fara a se gsndi zilnic la tratament.\u201d<\/p>\n<p style=\"text-align: justify\">Acest medicament a fost aprobat pentru tratament in \u0163ari din America de Nord, America de Sud, Orientul Mijlociu, Europa de Est precum \u015fi Australia \u015fi Elve\u0163ia. Peste 30.000 de oameni au fost trata\u0163i cu acest produs psna in prezent.<\/p>\n<p style=\"text-align: justify\"><strong>Despre Roche<\/strong><\/p>\n<p style=\"text-align: justify\">Roche este unul din pionerii globali ai industriei farmaceutice si de diagnostic, ce inoveaza continuu cu scopul de a imbunatati viata oamenilor. Sinergia dintre diviziile de Farmaceutice \u015fi Diagnostic au transformat Roche in lider global al medicinii personalizate, o strategie care isi propune sa ofere tratamentul potrivit pentru pacientul potrivit, in cele mai bune conditii posibile.<\/p>\n<p style=\"text-align: justify\">Roche este cea mai mare companie de biotehnologie la nivel mondial, ce ofera medicamente diferen\u0163iate clinic in domeniul oncologiei, imunologiei, bolilor infec\u0163ioase, oftalmologiei \u015fi afec\u0163iunilor sistemului nervos central. Roche este, de asemenea, lider mondial in diagnosticul in vitro \u015fi in diagnosticul histologic al cancerului, precum \u015fi pionier in managementul diabetului. Fondata in 1896, compania Roche este in permanenta in cautarea celor mai bune solutii pentru prevenirea, diagnosticarea si tratarea maladiilor, aducandu-si astfel o contributie sustenabila in societate. 29 de medicamente dezvoltate de Roche &#8211; printre care antibiotice, medicamente impotriva malariei \u015fi chimioterapice &#8211; sunt pe Lista Medicamentelor Esen\u0163iale elaborata de Organiza\u0163ia Mondiala a Sanata\u0163ii. De asemenea, compania Roche a fost recunoscuta opt ani consecutiv ca liderul sectorului farmaceutic al Dow Jones Sustenability Index.<\/p>\n<p style=\"text-align: justify\">Avsnd sediul central in Basel, Elve\u0163ia, Roche este prezenta in peste 100 tari, iar in 2016 compania avea peste 94.000 angajati la nivel global. In 2016, Roche a investit 9,9 miliarde de franci elvetieni in cercetare si dezvoltare, compania raportsnd vsnzari de 50,6 miliarde de franci elvetieni. Compania Genentech, din Statele Unite, este de\u0163inuta in totalitate de grupul Roche. De asemenea, Roche este ac\u0163ionarul majoritar al companiei Chugai Pharmaceutical, din Japonia.<\/p>\n<p style=\"text-align: justify\"><strong>Despre Roche Romania<\/strong><\/p>\n<p style=\"text-align: justify\">Prezent pe piata romaneasca inca din perioada interbelica, Roche isi redeschide reprezentanta locala in anul 1992.\u00a0 In anul 2005, grupul Roche ia decizia sa infiinteze societatea comerciala S.C. Roche Romania SRL, urmsnd ca activitatea reprezentantei din Bucuresti sa fie preluata de compania locala nou infiintata.<\/p>\n<p style=\"text-align: justify\">Roche ofera produse si servicii care acopera intreg spectrul ingrijirilor de sanatate, pornind de la preventie, tratament si psna la monitorizarea post-tratament, in arii terapeutice majore unde exista nevoi medicale neacoperite inca.\u00a0 Prin intermediul Roche Romsnia, ambele divizii ale Grupului Roche &#8211; divizia de farmaceutice si divizia de diagnostice &#8211; sunt prezente pe piata din tara noastra, oferind produse si servicii de inalta specializare. Pentru orice informatii suplimentare, va rugam sa accesati www.roche.ro.<\/p>\n<p style=\"text-align: justify\">Departamentul de Comunicare al Roche Romsnia: <a href=\"mailto:andrei.vlad@roche.com\">andrei.vlad@roche.com<\/a>, 0728292664<\/p>\n<p style=\"text-align: justify\"><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a>European Multiple Sclerosis Platform. MS Facts. Available at:\u00a0<a href=\"http:\/\/www.emsp.org\/about-ms\/\">http:\/\/www.emsp.org\/about-ms\/<\/a><\/p>\n<p style=\"text-align: justify\"><a href=\"#_ftnref2\" name=\"_ftn2\">[2]<\/a> Estimated from http:\/\/www.emsp.org\/wp-content\/uploads\/2015\/08\/MS-in-EU-access.pdf as 15% of total MS cases per country<\/p>\n<p style=\"text-align: justify\"><a href=\"#_ftnref3\" name=\"_ftn3\">[3]<\/a> National Multiple Sclerosis Society. Types of MS. Available at http:\/\/www.nationalmssociety.org\/What-is-MS\/Types-of-MS.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ocrevus &#8211; un nou medicament produs de Roche, pentru tratamentul formelor recurente de scleroza multipla si pentru forma primara progresiva, a fost aprobat in Uniunea Europeana Primul \u015fi unicul medicament [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":7607,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7606","post","type-post","status-publish","format-standard","has-post-thumbnail","category-stiri-noutati"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocrevus tratament pentru formele recurente de scleroza multipla<\/title>\n<meta name=\"description\" content=\"Ocrevus scleroza multipla\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jurmed.ro\/medici\/ocrevus\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocrevus tratament pentru formele recurente de scleroza multipla\" \/>\n<meta property=\"og:description\" content=\"Ocrevus scleroza multipla\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jurmed.ro\/medici\/ocrevus\/\" \/>\n<meta property=\"og:site_name\" content=\"Jurmed - Medici\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-15T12:56:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2018\/01\/Roche-Logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"480\" \/>\n\t<meta property=\"og:image:height\" content=\"283\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"costelv\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"costelv\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/\"},\"author\":{\"name\":\"costelv\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"headline\":\"Ocrevus &#8211; un medicament pentru tratamentul formelor recurente de scleroza multipla si pentru forma primara progresiva\",\"datePublished\":\"2018-01-15T12:56:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/\"},\"wordCount\":872,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2018\/01\/Roche-Logo.jpg\",\"articleSection\":[\"Stiri \/ Noutati\"],\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/jurmed.ro\/medici\/ocrevus\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/\",\"url\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/\",\"name\":\"Ocrevus tratament pentru formele recurente de scleroza multipla\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2018\/01\/Roche-Logo.jpg\",\"datePublished\":\"2018-01-15T12:56:46+00:00\",\"author\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"description\":\"Ocrevus scleroza multipla\",\"breadcrumb\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jurmed.ro\/medici\/ocrevus\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/#primaryimage\",\"url\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2018\/01\/Roche-Logo.jpg\",\"contentUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2018\/01\/Roche-Logo.jpg\",\"width\":480,\"height\":283,\"caption\":\"Atrofia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jurmed.ro\/medici\/ocrevus\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/jurmed.ro\/medici\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocrevus &#8211; un medicament pentru tratamentul formelor recurente de scleroza multipla si pentru forma primara progresiva\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\",\"url\":\"https:\/\/jurmed.ro\/medici\/\",\"name\":\"Jurmed - Medici\",\"description\":\"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jurmed.ro\/medici\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\",\"name\":\"costelv\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"caption\":\"costelv\"},\"url\":\"https:\/\/jurmed.ro\/medici\/author\/costelvoicu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocrevus tratament pentru formele recurente de scleroza multipla","description":"Ocrevus scleroza multipla","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jurmed.ro\/medici\/ocrevus\/","og_locale":"ro_RO","og_type":"article","og_title":"Ocrevus tratament pentru formele recurente de scleroza multipla","og_description":"Ocrevus scleroza multipla","og_url":"https:\/\/jurmed.ro\/medici\/ocrevus\/","og_site_name":"Jurmed - Medici","article_published_time":"2018-01-15T12:56:46+00:00","og_image":[{"width":480,"height":283,"url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2018\/01\/Roche-Logo.jpg","type":"image\/jpeg"}],"author":"costelv","twitter_misc":{"Scris de":"costelv","Timp estimat pentru citire":"4 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jurmed.ro\/medici\/ocrevus\/#article","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/ocrevus\/"},"author":{"name":"costelv","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"headline":"Ocrevus &#8211; un medicament pentru tratamentul formelor recurente de scleroza multipla si pentru forma primara progresiva","datePublished":"2018-01-15T12:56:46+00:00","mainEntityOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/ocrevus\/"},"wordCount":872,"commentCount":0,"image":{"@id":"https:\/\/jurmed.ro\/medici\/ocrevus\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2018\/01\/Roche-Logo.jpg","articleSection":["Stiri \/ Noutati"],"inLanguage":"ro-RO","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jurmed.ro\/medici\/ocrevus\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jurmed.ro\/medici\/ocrevus\/","url":"https:\/\/jurmed.ro\/medici\/ocrevus\/","name":"Ocrevus tratament pentru formele recurente de scleroza multipla","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/#website"},"primaryImageOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/ocrevus\/#primaryimage"},"image":{"@id":"https:\/\/jurmed.ro\/medici\/ocrevus\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2018\/01\/Roche-Logo.jpg","datePublished":"2018-01-15T12:56:46+00:00","author":{"@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"description":"Ocrevus scleroza multipla","breadcrumb":{"@id":"https:\/\/jurmed.ro\/medici\/ocrevus\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jurmed.ro\/medici\/ocrevus\/"]}]},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/ocrevus\/#primaryimage","url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2018\/01\/Roche-Logo.jpg","contentUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2018\/01\/Roche-Logo.jpg","width":480,"height":283,"caption":"Atrofia"},{"@type":"BreadcrumbList","@id":"https:\/\/jurmed.ro\/medici\/ocrevus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/jurmed.ro\/medici\/"},{"@type":"ListItem","position":2,"name":"Ocrevus &#8211; un medicament pentru tratamentul formelor recurente de scleroza multipla si pentru forma primara progresiva"}]},{"@type":"WebSite","@id":"https:\/\/jurmed.ro\/medici\/#website","url":"https:\/\/jurmed.ro\/medici\/","name":"Jurmed - Medici","description":"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jurmed.ro\/medici\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":"Person","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d","name":"costelv","image":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","caption":"costelv"},"url":"https:\/\/jurmed.ro\/medici\/author\/costelvoicu\/"}]}},"_links":{"self":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/7606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/comments?post=7606"}],"version-history":[{"count":1,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/7606\/revisions"}],"predecessor-version":[{"id":7608,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/7606\/revisions\/7608"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/media\/7607"}],"wp:attachment":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/media?parent=7606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/categories?post=7606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/tags?post=7606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}